Specific effect of immunomodulatory quinoline-3-carboxamide ABR-215757 in GM-CSF stimulated bone marrow cell cultures: Block of initiation of proliferation of Gr-1+ cells

International Immunopharmacology

Volumn 11, Issue 8, 2011, Pages 1045-1051

  Helmersson, Sofia ^a   Stenström, Martin ^b   Leanderson, Tomas ^a   Ivars, Fredrik ^a  

^a LUND UNIVERSITY   (Sweden)

^b Active Biotech Research AB   (Sweden)

Author keywords

Bone marrow; Carboxamide; GM CSF; Myeloid cell

Indexed keywords

ABR 215757; AMIDE; CALGRANULIN A; CALGRANULIN B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; QUINOLINE 3 CARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL MATURATION; CELL PROLIFERATION; DENDRITIC CELL; DRUG EFFECT; GRANULOCYTE; IMMUNOMODULATION; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84860404211     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.02.025     Document Type: Article

References (23)

1. Bjork J, Kleinau S. Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice. Agents Actions 1989;27:319-21. (Pubitemid 19188631)
2. Brunmark C, Runstrom A, Ohlsson L, Sparre B, Brodin T, Astrom M, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002;130:163-72. (Pubitemid 35240003)
3. Gross DJ, Weiss L, Reibstein I, Hedlund G, Dahlen E, Rapoport MJ, et al. The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus. Int Immunopharmacol 2001;1:1131-9. (Pubitemid 32434429)
4. Runstrom A, Leanderson T, Ohlsson L, Axelsson B. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR- 215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 2006;173:69-78.
5. Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009;7:e97.
6. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009;325:612-6.
7. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003;19:71-82. (Pubitemid 36859902)
8. Naik SH, Metcalf D, van Nieuwenhuijze A, Wicks I, Wu L, O'Keeffe M, et al. Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat Immunol 2006;7:663-71. (Pubitemid 43797348)
9. Serbina NV, Salazar-Mather TP, Biron CA, Kuziel WA, Pamer EG. TNF/iNOSproducing dendritic cells mediate innate immune defense against bacterial infection. Immunity 2003;19:59-70. (Pubitemid 36859901)
10. Xu Y, Zhan Y, Lew AM, Naik SH, Kershaw MH. Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J Immunol 2007;179:7577-84.
11. Cheong C, Matos I, Choi JH, Dandamudi DB, Shrestha E, Longhi MP, et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell.143:416-29.
12. Pronk CJ, Rossi DJ, Mansson R, Attema JL, Norddahl GL, Chan CK, et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell 2007;1:428-42. (Pubitemid 47506534)
13. Lu L, Bonham CA, Chambers FG, Watkins SC, Hoffman RA, Simmons RL, et al. Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J Immunol 1996;157:3577-86. (Pubitemid 126449172)
14. Rossner S, Voigtlander C, Wiethe C, Hanig J, Seifarth C, Lutz MB. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol 2005;35:3533-44. (Pubitemid 43025534)
15. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007;81:28-37. (Pubitemid 46021248)
16. Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001;70:849-60. (Pubitemid 33151123)
17. Naik SH. Demystifying the development of dendritic cell subtypes, a little. Immunol Cell Biol 2008;86:439-52. (Pubitemid 351948216)
18. Fancke B, Suter M, Hochrein H, O'Keeffe M. M-CSF: a novel plasmacytoid and conventional dendritic cell poietin. Blood 2008;111:150-9.
19. Galelli A, Chedid L. Modulation of myelopoiesis in vivo by synthetic adjuvantactive muramyl peptides: induction of colony-stimulating activity and stimulation of stem cell proliferation. Infect Immun 1983;42:1081-5. (Pubitemid 14244380)
20. Fletcher HA, Keyser A, Bowmaker M, Sayles PC, Kaplan G, Hussey G, et al. Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth. BMC Med Genet 2009;2:10.
21. Luo Y, Chen X, O'Donnell MA. Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol 2007;147:370-8. (Pubitemid 46096016)
22. Stenstrom M, Anderson P, Eroukhmanoff L, Leanderson T, Ivars F. Selective depletion of splenic CD4 dendritic cells in mice treated with immunomodulatory quinoline-3-carboxamide ABR-215757. Int. Immunopharmacol.10:837-42.
23. Naik SH, Proietto AI, Wilson NS, Dakic A, Schnorrer P, Fuchsberger M, et al. Cutting edge: generation of splenic CD8+ and CD8-dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J Immunol 2005;174:6592-7. (Pubitemid 40705619)